Sanofi and CD&R Negotiate Stake in Consumer Health Unit Opella

Sanofi and private equity firm Clayton, Dubilier & Rice (CD&R) have entered into exclusive negotiations regarding the potential sale of a 50% controlling stake in Sanofi's consumer healthcare division, Opella. Sanofi would retain a significant minority shareholding following the transaction.

The proposed deal values Opella at approximately €16 billion. Sanofi stated the move aligns with its strategy to focus more heavily on developing innovative medicines and vaccines. Opella operates in over 100 countries and owns brands such as Allegra, Doliprane, and Dulcolax.

CD&R is expected to contribute its industry expertise and global network to support Opella's growth as a standalone entity. French state-backed investment company Bpifrance is also anticipated to join as a minority shareholder.

If finalized, the transaction would mark Opella's transition towards becoming an independent global consumer healthcare company. The deal is currently anticipated to close in the second quarter of 2025 at the earliest.